- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0428
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Diabetes, bone and glucose-lowering agents: basic biology ; volume:60 ; number:7 ; day:22 ; month:4 ; year:2017 ; pages:1163-1169 ; date:7.2017
Diabetologia ; 60, Heft 7 (22.4.2017), 1163-1169, 7.2017
- Schlagwort
-
Endokrinologie
- Urheber
-
Lecka-Czernik, Beata
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00125-017-4269-4
- URN
-
urn:nbn:de:1111-201706245176
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lecka-Czernik, Beata
- SpringerLink (Online service)
Ähnliche Objekte (12)
Selective amyloid-β lowering agents
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Basic biology
Critical Appraisal of Amyloid Lowering Agents in AD
Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
Cardiovascular outcome trials of glucose-lowering medications: an update
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Basic techniques in molecular biology
Selective amyloid-β lowering agents
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Basic biology
Critical Appraisal of Amyloid Lowering Agents in AD
Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
Cardiovascular outcome trials of glucose-lowering medications: an update
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Basic techniques in molecular biology
Selective amyloid-β lowering agents
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Basic biology
Critical Appraisal of Amyloid Lowering Agents in AD
Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
Cardiovascular outcome trials of glucose-lowering medications: an update
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes